Daunorubicin/cytarabine

Daunorubicin/cytarabine
	Cytarabine
	Daunorubicin
Combination of
Daunorubicin	Anthracycline
Cytarabine	Antimetabolite
Clinical data
Trade names	Vyxeos
Other names	CPX-351
AHFS/Drugs.com	Monograph
License data	US DailyMed: Vyxeos;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01XY01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: WARNINGRx-only; EU: Rx-only;
Identifiers
CAS Number	1256639-86-7;
KEGG	D11390;

Daunorubicin/cytarabine is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.